Premium
FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL)
Author(s) -
Horwitz S.M.,
Scarisbrick J.,
Prince H.M.,
Whittaker S.,
Duvic M.,
Kim Y.H.,
Quaglino P.,
Zinzani P.L.,
Bechter O.,
Eradat H.,
PinterBrown L.,
Akilov O.,
Geskin L.,
Sanches J.,
OrtizRomero P.,
Lisano J.,
Brown L.,
PalancaWessels M.C.,
Gautam A.,
Bunn V.,
Little M.,
Dummer R.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.96_2630
Subject(s) - brentuximab vedotin , mycosis fungoides , medicine , cd30 , population , gastroenterology , cutaneous t cell lymphoma , oncology , lymphoma , surgery , nuclear medicine , environmental health
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom